Evidence map›Paper›PMID 42156944›Full record

Trial reportBone marrow transplantation2026

Von Willebrand factor and factor VIII as potential biomarkers for diagnosis and disease monitoring in chronic graft-versus-host disease.

Antonela Lelas, Lana Desnica, Ivan Sabol, Desiree Coen Herak, Marija Milos, Ana Zelic Kerep, Ante Vulic, Nadira Durakovic, Ranka Serventi-Seiwerth, Zinaida Peric and 3 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Antonela LelasUniversity Hospital Centre Zagreb, Zagreb, Croatia.ORCID 0009-0007-8564-9544
Lana DesnicaUniversity Hospital Centre Zagreb, Zagreb, Croatia.
Ivan SabolRudjer Boskovic Institute, Zagreb, Croatia.
Desiree Coen HerakUniversity Hospital Centre Zagreb, Zagreb, Croatia.ORCID 0000-0001-8327-9913
Marija MilosUniversity Hospital Centre Zagreb, Zagreb, Croatia.
Ana Zelic KerepUniversity Hospital Centre Zagreb, Zagreb, Croatia.ORCID 0000-0001-9186-2586
Ante VulicUniversity Hospital Centre Zagreb, Zagreb, Croatia.
Nadira DurakovicUniversity Hospital Centre Zagreb, Zagreb, Croatia.ORCID 0000-0001-5842-0911
Ranka Serventi-SeiwerthUniversity Hospital Centre Zagreb, Zagreb, Croatia.
Zinaida PericUniversity Hospital Centre Rijeka, Rijeka, Croatia.
Radovan VrhovacUniversity Hospital Centre Zagreb, Zagreb, Croatia.ORCID 0000-0003-3323-3487
Steven Z PavleticNational Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-9111-9354
Drazen PulanicUniversity Hospital Centre Zagreb, Zagreb, Croatia. drazen.pulanic@kbc-zagreb.hr.ORCID 0009-0004-3755-4477

Funding

Hrvatska Zaklada za Znanost (Croatian Science Foundation) IP-2016-06-8046
6 · The paper itself

Abstract

The identification of biomarkers of chronic Graft-versus-Host Disease (cGvHD) remains an unmet clinical need. Elevated von Willebrand factor (VWF) and factor VIII (FVIII) reflect inflammation and endothelial activation and might be interesting candidates for biomarkers of cGvHD. This prospective study evaluated 83 cGvHD patients and 39 allogeneic hematopoietic stem cell transplants recipients without cGvHD. VWF antigen (VWF:Ag), VWF activity (VWF:Ac), and FVIII activity were significantly elevated in cGvHD patients (p  <  0.001), with the highest levels observed in active disease. Higher VWF:Ag and VWF:Ac were associated with liver and oral cGvHD. In multivariate analysis, lower albumin was the strongest predictor of both higher VWF:Ag (R² = 0.576) and higher VWF:Ac (R² = 0.540), followed by older age, higher LDH, and number of affected organs. For higher FVIII, systemic immunosuppressive therapy emerged as the main predictor (R² = 0.247). Longitudinal analysis showed declining levels of these factors with cGvHD remission and persistent elevation in active disease. ROC analysis demonstrated diagnostic potential for early cGvHD of VWF:Ag >246.3% (AUC = 0.733) and VWF:Ac >271.4% (AUC = 0.728). These results show the potential of VWF and FVIII as novel biomarkers for diagnosis and disease activity in cGvHD. Additional validation in independent cohorts is warranted.

Indexed as

Factor VIIIGraft vs Host DiseaseHematopoietic Stem Cell Transplantationvon Willebrand FactorAdolescentAdultAgedBiomarkersChronic DiseaseFemaleHumansMaleMiddle AgedProspective StudiesYoung AdultBiomarkersF8 protein, humanFactor VIIIvon Willebrand Factor

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.